Drug intelligence / Profile preview

αvβ3 CAR-T cells

Development stage: Preclinical
Lead developer: Scripps Research
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

αvβ3 CAR-T cells are a type of Chimeric Antigen Receptor (CAR) T-cell therapy engineered to specifically target the αvβ3 integrin. This cell therapy is being investigated for its potential in treating breast cancer brain metastasis (BCBM). Pre-clinical studies have demonstrated that when combined with focused ultrasound-mediated blood-brain barrier opening (FUS BBBO), αvβ3 CAR-T cells significantly constrain BCBM outgrowth compared to monotherapy. The FUS BBBO appears to enhance the frequency of circulating CAR-T cells and increase the proportion of CD8+ CAR-T cells within BCBM-bearing brains, leading to elevated tumor-localized T cell infiltration.

Targets

αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on αvβ3 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on αvβ3 CAR-T cells.

Explore the full profile